Log in
NASDAQ:AXON

Axovant Sciences Stock Forecast, Price & News

$4.09
+0.44 (+12.05 %)
(As of 09/18/2020 12:00 AM ET)
Add
Compare
Today's Range
$3.63
Now: $4.09
$4.15
50-Day Range
$1.22
MA: $3.02
$3.65
52-Week Range
$0.93
Now: $4.09
$6.59
Volume3.23 million shs
Average Volume1.53 million shs
Market Capitalization$500.12 million
P/E RatioN/A
Dividend YieldN/A
Beta1.21
Axovant Sciences Ltd., a clinical-stage biopharmaceutical company, engages in acquisition, development, and commercialization of therapeutics in the fields of neurology and psychiatry in the United States and the European Union. It focuses on developing AXO-Lenti-PD, an in vivo lentiviral gene therapy investigational product candidate for the one-time treatment of Parkinson's disease. The company is also developing nelotanserin, a selective 5-HT2A receptor inverse agonist, which is in Phase II clinical trial for the treatment of visual hallucinations in patients with Lewy body dementia (LBD) and REM sleep behavior disorder in patients with LBD. In addition, it focuses on developing RVT-104, a combination of rivastigmine and a peripheral muscarinic receptor antagonist as treatments for patients with Alzheimer's disease or DLB. The company was formerly known as Roivant Neurosciences Ltd. and changed its name to Axovant Sciences Ltd. in March 2015. The company was founded in 2014 and is based in London, the United Kingdom. Axovant Sciences Ltd. is a subsidiary of Roivant Sciences Ltd.
Read More
Axovant Sciences logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.31 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:AXON
CUSIPN/A
Phone44-20-3318-9708

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$0.19 per share

Profitability

Net Income$-221,570,000.00

Miscellaneous

EmployeesN/A
Market Cap$500.12 million
Next Earnings DateN/A
OptionableOptionable
$4.09
+0.44 (+12.05 %)
(As of 09/18/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive AXON News and Ratings via Email

Sign-up to receive the latest news and ratings for AXON and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Axovant Sciences (NASDAQ:AXON) Frequently Asked Questions

How has Axovant Sciences' stock price been impacted by Coronavirus?

Axovant Sciences' stock was trading at $2.82 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, AXON shares have increased by 45.0% and is now trading at $4.09.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Axovant Sciences?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Axovant Sciences in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Axovant Sciences
.

How were Axovant Sciences' earnings last quarter?

Axovant Sciences Ltd (NASDAQ:AXON) posted its earnings results on Thursday, February, 7th. The biotechnology company reported ($0.27) EPS for the quarter, hitting the consensus estimate of ($0.27).
View Axovant Sciences' earnings history
.

What price target have analysts set for AXON?

1 brokerages have issued 1 year target prices for Axovant Sciences' shares. Their forecasts range from $32.00 to $32.00. On average, they anticipate Axovant Sciences' stock price to reach $32.00 in the next twelve months. This suggests a possible upside of 682.4% from the stock's current price.
View analysts' price targets for Axovant Sciences
.

Who are some of Axovant Sciences' key competitors?

What other stocks do shareholders of Axovant Sciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Axovant Sciences investors own include Novavax (NVAX), NVIDIA (NVDA), Netflix (NFLX), Alibaba Group (BABA), Canopy Growth (CGC), Micron Technology (MU), TherapeuticsMD (TXMD), ACADIA Pharmaceuticals (ACAD), Zynerba Pharmaceuticals (ZYNE) and Arena Pharmaceuticals (ARNA).

Who are Axovant Sciences' key executives?

Axovant Sciences' management team includes the following people:
  • Dr. Pavan Cheruvu M.D., CEO & Director (Age 37)
  • Dr. Gregory M. Weinhoff, Principal Financial & Accounting Officer (Age 48)
  • Mr. Mark Altmeyer, Pres & Chief Commercial Officer of Axovant Sciences GmbH (Age 58)
  • Dr. David T. Hung, Scientific Advisor of Group (Age 61)
  • Dr. Fraser Wright, Chief Technology Officer

When did Axovant Sciences IPO?

(AXON) raised $251 million in an initial public offering (IPO) on Thursday, June 11th 2015. The company issued 17,900,000 shares at $13.00-$15.00 per share. Jefferies, Evercore ISI and RBC Capital Markets acted as the underwriters for the IPO and JMP Securities and Baird were co-managers.

What is Axovant Sciences' stock symbol?

Axovant Sciences trades on the NASDAQ under the ticker symbol "AXON."

How do I buy shares of Axovant Sciences?

Shares of AXON can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Axovant Sciences' stock price today?

One share of AXON stock can currently be purchased for approximately $4.09.

How big of a company is Axovant Sciences?

Axovant Sciences has a market capitalization of $500.12 million. The biotechnology company earns $-221,570,000.00 in net income (profit) each year or ($2.06) on an earnings per share basis.

What is Axovant Sciences' official website?

The official website for Axovant Sciences is www.axovant.com.

How can I contact Axovant Sciences?

Axovant Sciences' mailing address is 20-22 BEDFORD ROW, LONDON X0, WC1R 4JS. The biotechnology company can be reached via phone at 44-20-3318-9708.

This page was last updated on 9/19/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.